EP4031569A4 - Anticorps anti-facteur de cellules souches et leurs procédés d'utilisation - Google Patents

Anticorps anti-facteur de cellules souches et leurs procédés d'utilisation Download PDF

Info

Publication number
EP4031569A4
EP4031569A4 EP20866530.7A EP20866530A EP4031569A4 EP 4031569 A4 EP4031569 A4 EP 4031569A4 EP 20866530 A EP20866530 A EP 20866530A EP 4031569 A4 EP4031569 A4 EP 4031569A4
Authority
EP
European Patent Office
Prior art keywords
methods
stem cell
cell factor
factor antibodies
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20866530.7A
Other languages
German (de)
English (en)
Other versions
EP4031569A1 (fr
Inventor
Martin Phillips
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Opsidio LLC
Original Assignee
Opsidio LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Opsidio LLC filed Critical Opsidio LLC
Publication of EP4031569A1 publication Critical patent/EP4031569A1/fr
Publication of EP4031569A4 publication Critical patent/EP4031569A4/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP20866530.7A 2019-09-16 2020-09-16 Anticorps anti-facteur de cellules souches et leurs procédés d'utilisation Pending EP4031569A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962900927P 2019-09-16 2019-09-16
PCT/US2020/050973 WO2021055408A1 (fr) 2019-09-16 2020-09-16 Anticorps anti-facteur de cellules souches et leurs procédés d'utilisation

Publications (2)

Publication Number Publication Date
EP4031569A1 EP4031569A1 (fr) 2022-07-27
EP4031569A4 true EP4031569A4 (fr) 2023-10-18

Family

ID=74868426

Family Applications (2)

Application Number Title Priority Date Filing Date
EP20866530.7A Pending EP4031569A4 (fr) 2019-09-16 2020-09-16 Anticorps anti-facteur de cellules souches et leurs procédés d'utilisation
EP20865210.7A Pending EP4031176A4 (fr) 2019-09-16 2020-09-16 Anticorps anti-facteur de cellules souches et leurs procédés d'utilisation dans une maladie rénale

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP20865210.7A Pending EP4031176A4 (fr) 2019-09-16 2020-09-16 Anticorps anti-facteur de cellules souches et leurs procédés d'utilisation dans une maladie rénale

Country Status (20)

Country Link
US (5) US11939373B2 (fr)
EP (2) EP4031569A4 (fr)
JP (2) JP2022548646A (fr)
KR (1) KR20220079561A (fr)
CN (2) CN114729036B (fr)
AR (1) AR119979A1 (fr)
AU (2) AU2020348295A1 (fr)
BR (1) BR112022004776A2 (fr)
CA (2) CA3154648A1 (fr)
CL (1) CL2022000633A1 (fr)
CO (1) CO2022003661A2 (fr)
DO (1) DOP2022000058A (fr)
EC (1) ECSP22022676A (fr)
IL (1) IL291385A (fr)
MX (1) MX2022003159A (fr)
PE (1) PE20230090A1 (fr)
TW (1) TW202124434A (fr)
UY (1) UY38883A (fr)
WO (2) WO2021055408A1 (fr)
ZA (1) ZA202203272B (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022004776A2 (pt) 2019-09-16 2022-06-21 Opsidio Llc Anticorpos anti-fator de células-tronco e métodos para uso dos mesmos

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6541090A (en) * 1989-10-16 1991-05-16 Amgen, Inc. Stem cell factor
US5911988A (en) 1995-04-28 1999-06-15 Bayer Corporation Method for treating asthma using SCF antibody
AR037756A1 (es) 2001-12-17 2004-12-01 Bayer Corp Anticuerpo que inhibe la actividad del factor de las celulas precursoras y su uso para el tratamiento del asma.
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
PL1691837T3 (pl) * 2003-12-10 2012-11-30 Squibb & Sons Llc IP-10 przeciwciała i ich zastosowanie
EP1745076B1 (fr) * 2004-04-29 2012-06-13 Otsuka Pharmaceutical Co., Ltd. Anticorps diriges contre la glycoproteine vi et procedes associes
US20080248050A1 (en) * 2006-06-30 2008-10-09 Uchicago Argonne, Llc Meta-specific vaccine, method for treating patients immunized with meta-specific vaccine
US20110189093A1 (en) * 2008-04-14 2011-08-04 Proscan Rx Pharma Prostate specific membrane antigen antibodies and antigen binding fragments
GB2559498B (en) * 2011-01-10 2018-10-24 Univ Michigan Regents Stem cell factor inhibitor
KR101384360B1 (ko) * 2012-05-04 2014-04-14 아주대학교산학협력단 Ｓｃｆ 또는 이의 수용체를 억제하는 물질을 포함하는 혈관 투과성 관련 질환의 치료 또는 예방용 조성물
WO2015006554A1 (fr) 2013-07-10 2015-01-15 The Regents Of The University Of Michigan Anticorps thérapeutiques et utilisations de ceux-ci
PE20180556A1 (es) * 2015-08-19 2018-04-02 Pfizer Anticuerpos inhibidores via del factor tisular y usos de los mismos
EP3393516A1 (fr) * 2015-12-22 2018-10-31 AbbVie Stemcentrx LLC Nouveaux anticorps anti-upk1b et méthodes d'utilisation
BR112022004776A2 (pt) 2019-09-16 2022-06-21 Opsidio Llc Anticorpos anti-fator de células-tronco e métodos para uso dos mesmos

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FONSECA WENDY ET AL: "Group 2 innate lymphoid cells (ILC2) are regulated by stem cell factor during chronic asthmatic disease", MUCOSAL IMMUNOLOGY, vol. 12, no. Suppl. 5, 7 January 2019 (2019-01-07), New York, pages 1 - 12, XP055807780, ISSN: 1933-0219, DOI: 10.1038/s41385-018-0117-1 *

Also Published As

Publication number Publication date
CA3154649A1 (fr) 2021-03-25
CO2022003661A2 (es) 2022-04-08
MX2022003159A (es) 2022-04-07
US11939373B2 (en) 2024-03-26
IL291385A (en) 2022-05-01
US20220340655A1 (en) 2022-10-27
AU2020351138A1 (en) 2022-03-31
CN114729036A (zh) 2022-07-08
KR20220079561A (ko) 2022-06-13
EP4031176A1 (fr) 2022-07-27
US20230019680A1 (en) 2023-01-19
AR119979A1 (es) 2022-01-26
CN114729036B (zh) 2024-07-02
BR112022004776A2 (pt) 2022-06-21
EP4031176A4 (fr) 2023-11-29
CN118561997A (zh) 2024-08-30
ZA202203272B (en) 2022-12-21
WO2021055409A1 (fr) 2021-03-25
WO2021055408A1 (fr) 2021-03-25
ECSP22022676A (es) 2022-05-31
EP4031569A1 (fr) 2022-07-27
US20240076367A1 (en) 2024-03-07
UY38883A (es) 2021-04-30
CL2022000633A1 (es) 2022-11-11
US20220324957A1 (en) 2022-10-13
DOP2022000058A (es) 2022-08-31
AU2020348295A1 (en) 2022-04-07
CA3154648A1 (fr) 2021-03-25
JP2022547733A (ja) 2022-11-15
US20210079084A1 (en) 2021-03-18
TW202124434A (zh) 2021-07-01
JP2022548646A (ja) 2022-11-21
PE20230090A1 (es) 2023-01-16

Similar Documents

Publication Publication Date Title
EP4031177A4 (fr) Anticorps anti-tnfr2 et méthodes d'utilisation
EP3852805A4 (fr) Anticorps anti-lilrb2 et leurs méthodes d'utilisation
EP3917564A4 (fr) Anticorps anti-claudine 18 et leurs méthodes d'utilisation
EP3826676A4 (fr) Nouveaux anticorps anti-cd47 et leurs méthodes d'utilisation
EP3947647A4 (fr) Procédés pour la production de cellules nk car et leur utilisation
EP3947688A4 (fr) Récepteurs de lymphocytes t et leurs procédés d'utilisation
EP3743447A4 (fr) Anticorps anti-b7-h4 et leurs procédés d'utilisation
EP3986938A4 (fr) Récepteurs de lymphocytes t mage-a4 et leurs procédés d'utilisation
EP3966248A4 (fr) Anticorps humanisés dirigés contre la mucine-16 et leurs procédés d'utilisation
EP3930756A4 (fr) Anticorps se liant à lilrb4 et ses méthodes d'utilisation
EP4067385A4 (fr) Anticorps monoclonal de détection de cellules car-t, trousse et application
EP3740509A4 (fr) Anticorps anti-pd-l1 et méthodes d'utilisation
EP4061852A4 (fr) Anticorps dirigés contre tie-2 et méthodes d'utilisation
EP3994174A4 (fr) Anticorps anti-fzd monospecifiques et méthodes d'utilisation
EP4007605A4 (fr) Anticorps anti-fcrn et leurs procédés d'utilisation
EP3746484A4 (fr) Anticorps anti-ms4a6a et leurs procédés d'utilisation
EP4061848A4 (fr) Anticorps anti-ror-2 et méthodes d'utilisation
ZA202203272B (en) Anti-stem cell factor antibodies and methods of use thereof
EP4061847A4 (fr) Anticorps monoclonal anti-b7-h3 et ses procédés d'utilisation
SG11202113221RA (en) Anti-cd137l antibodies and methods of using same
EP3880714A4 (fr) Anticorps dirigés contre la mucine-16 et leurs procédés d'utilisation
EP3947452A4 (fr) Anticorps anti-récepteur nmda et procédés d'utilisation
EP4004217A4 (fr) Récepteurs de lymphocytes t et leurs procédés d'utilisation
EP3935177A4 (fr) Récepteurs de lymphocytes t et leurs procédés d'utilisation
EP3935172A4 (fr) Récepteurs de lymphocytes t et leurs procédés d'utilisation

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220408

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40078116

Country of ref document: HK

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230425

A4 Supplementary search report drawn up and despatched

Effective date: 20230918

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 16/22 20060101AFI20230912BHEP